ACAD
31.88
0.00
0.00%
AEMD
0.26
+0.01
+3.60%
APRI
1.22
0.00
0.00%
ARNA
4.55
0.00
0.00%
ATEC
1.37
0.00
0.00%
CFN
59.77
0.00
0.00%
CNAT
5.34
0.00
0.00%
CRXM
0.2
+0.02
+11.11%
CYTX
0.48
0.00
0.00%
DXCM
57.94
0.00
0.00%
GNMK
13.15
0.00
0.00%
HALO
13.87
0.00
0.00%
ILMN
197.16
0.00
0.00%
INNV
0.25
+0.01
+4.17%
INO
8.61
0.00
0.00%
ISCO
0.06
0.00
-4.76%
ISIS
71.28
0.00
0.00%
LGND
54.67
-1.16
-2.08%
LPTN
2.96
0.00
0.00%
MBVX
1.14
-0.11
-8.80%
MEIP
3.69
0.00
0.00%
MNOV
3.55
0.00
0.00%
MRTX
19.27
0.00
0.00%
MSTX
0.47
0.00
0.00%
NBIX
31.7
0.00
0.00%
NUVA
46.76
0.00
0.00%
ONCS
0.4
+0.00
+0.25%
ONVO
6.32
0.00
0.00%
OREX
5.41
0.00
0.00%
OTIC
32.93
0.00
0.00%
QDEL
24.32
0.00
0.00%
RCPT
110.1
0.00
0.00%
RGLS
18.54
0.00
0.00%
RMD
65.24
0.00
0.00%
SCIE
0.01
0.00
-7.75%
SPHS
0.46
0.00
0.00%
SRNE
9.97
0.00
0.00%
TROV
5.8
0.00
0.00%
VICL
1.04
0.00
0.00%
VOLC
17.97
0.00
0.00%
ZGNX
1.28
0.00
0.00%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12

January 5, 2015 – 2:05 pm | Edit Post
Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12

DUBLIN, Jan. 5, 2015 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 

Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 12, 2015 at 10:00 a.m. PST / 6:00 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq:  JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

 

SOURCE Jazz Pharmaceuticals plc

Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

January 5, 2015 – 10:57 am | Edit Post
Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria.

Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

January 5, 2015 – 10:57 am | Edit Post
Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria.

Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

January 5, 2015 – 10:57 am | Edit Post
Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego Sc…

Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

January 5, 2015 – 10:57 am | Edit Post
Fat Isn’t All Bad: Skin Adipocytes Help Protect Against Infections

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of C…

Diet drug fools the gut

January 5, 2015 – 9:02 am | Edit Post

A potential weight-loss drug tricks the body into thinking it’s been fed.

Diet drug fools the gut

January 5, 2015 – 9:02 am | Edit Post

A potential weight-loss drug tricks the body into thinking it’s been fed.

Diet drug fools the gut

January 5, 2015 – 9:02 am | Edit Post

A potential weight-loss drug tricks the body into thinking it’s been fed.

PAREXEL International To Present At JP Morgan Healthcare Conference

January 5, 2015 – 8:00 am | Edit Post
PAREXEL International To Present At JP Morgan Healthcare Conference

BOSTON, Jan. 5, 2015 /PRNewswire/ — PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the JP Morgan Healthcare Conference on Wednesday, January 14, 2015, in San Francisco.  Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 11:00 a.m. PT.

A live webcast of the presentation will be available through the “Investors” section of PAREXEL’s website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website for 90 days after the presentation.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 15,980 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

Contact:
Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@parexel.com

SOURCE PAREXEL International Corporation

Symic Biomedical Announces Collaboration with Nordic Biosciences for its Osteoarthritis Program

January 5, 2015 – 7:39 am | Edit Post
Symic Biomedical Announces Collaboration with Nordic Biosciences for its Osteoarthritis Program

– Strategic partnership to focus on development and execution of clinical trial programs through FDA approval– Initial clinical study in osteoarthritis of the knee expected to start enrollment in early 2016.

SAN FRANCISCO, Jan. 5, 2015 /PRNewswire/ — Symic Biomedical today announced a strategic alliance with Nordic Bioscience A/S to focus on the clinical development of Symic’s osteoarthritis (OA) program. Nordic Bioscience (Copenhagen, Denmark) is a world-renowned pharmaceutical development organization with scientific and clinical expertise in the OA field, and pioneers in the biomarker space with full translational and regulatory implementation capabilities. Nordic Bioscience has previously run or is running clinical programs in OA for Novartis Pharma AG and Merck Serono, and Nordic’s expertise in OA combined with Symic’s proprietary and novel compounds for treating OA creates exciting potential for a disease that lacks effective treatment and affects so many people world-wide.

Under the terms of the agreement, Nordic Bioscience will provide clinical development services to Symic on a shared-risk basis in exchange for a payment structure that includes service fees and equity in Symic’s OA subsidiary. Symic retains responsibility for the development and commercialization of the products. Financial terms of the agreement were not disclosed.

“Symic is developing a new category of therapeutics with a wide variety of clinical applications. As a company our goal is to find the best option for development of each of our programs,” said Ken Horne, Chief Executive Officer of Symic Biomedical. “With Nordic Bioscience’s expertise in OA, we have clearly found the best possible option for Symic’s OA program.” Morten Karsdal, Chief Executive Officer of Nordic Bioscience, added “Nordic Bioscience is excited to be partnering with Symic on their novel and exciting OA program. OA is a clinical area that Nordic Bioscience has extensive experience in, and our biomarker expertise lends itself particularly well to Symic’s therapeutic approach.”

Osteoarthritis, also called degenerative joint disease, is a disorder of the joints characterized by progressive deterioration of cartilage and other surrounding tissues. It is the most common cause of disability in older adults and the lifetime risk of developing symptomatic knee OA is estimated to be 40% in men and 47% in women.

About Symic Biomedical (www.symicbio.com)
Symic Biomedical is a developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease.  Symic’s compounds function like proteoglycans, important structural and functional macromolecules native to the ECM (extracellular matrix) that are known to protect against tissue degradation and promote healing during illness or injury. The ECM is the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, including proteoglycans, play a critical role in maintaining tissue function and healing upon injury or in chronic diseases. Symic is targeting the ECM using its proprietary proteoglycan mimics, and will advance its compounds in a variety of acute and chronic therapeutic areas with unmet clinical needs.

SOURCE Symic Biomedical